Videos

Ross Mudgway, BS, explains how a multidisciplinary approach as well as open discussions with the patient can help determine the best course of action for patients with metastatic breast cancer.

Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, shares updated overall survival data from the phase III COLUMBUS trial examining encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.

Metastatic Cutaneous Squamous Cell Carcinoma

Mansoor Mirza, MD, chief oncologist, Department of Oncology, Copenhagen University Hospital, discusses the findings from NSGO-AVANOVA2/ENGOT-OV24, the randomized controlled chemotherapy-free study of niraparib (Zejula) and bevacizumab (Avastin) versus niraparib alone in recurrent platinum-sensitive ovarian cancer.

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses results from the protocol-specified final analysis of the phase III KEYNOTE-048 trial of pembrolizumab (Keytruda) as frontline therapy for recurrent/metastatic head and neck squamous cell carcinoma.

Karim Fizazi, MD, PhD, professor and head of the GARD Inpatient Unit, at Institut Gustave Roussy, discusses the impact of darolutamide (ODM-201) on pain and quality of life in patients with nonmetastatic castration-resistant prostate cancer. 

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, at Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, at Harvard Medical School, highlights key trials in kidney cancer presented at the 2019 ASCO Annual Meeting.

Robyn M. Scherber, MD, MPH, discusses her advice for treating patients with myelofibrosis that become refractory or resistant to ruxolitinib.

Rozita Yarmand, PhD, discusses the take home message from the current research in medullary thyroid cancer.

Chronic Myeloid Leukemia

Jeremie Calais, MD, discusses the results from a preliminary analysis of a phase II trial investigating 177 lutetium prostate-specific membrane antigen-617 in patients with metastatic castration-resistant prostate cancer.

Ahmed Omar Kaseb, MD, discusses the current treatment landscape for patients with hepatocellular carcinoma.

Benjamin P. Levy, MD, discusses the evolution of liquid biopsies in all solid tumors, especially in non–small cell lung cancer (NSCLC) where they are used routinely.